Lv2
128 积分 2025-08-25 加入
Urinary tract infections: pathogenesis, host susceptibility and emerging therapeutics
4小时前
待确认
Glomerulonephritis: immunopathogenesis and immunotherapy
6小时前
已完结
The ImproveCareNow Registry: Prediction of remission rates in paediatric Crohn's disease
15天前
已关闭
Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study
15天前
已完结
Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study
15天前
已完结
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease
15天前
已完结
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
15天前
已完结
Are all the IL-23 blockers the same in inflammatory bowel disease?
15天前
已完结
Host–pathobiont interactions in Crohn’s disease
23天前
已完结
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
1个月前
已完结
皖公网安备34019202002308
